Purpose Nausea and vomiting (NV) related to DMSO affect patients undergoing auto-SCT despite antiemetic measures. Orange flavoring may reduce gastrointestinal symptoms. Methods A multicenter, randomized, three-arm, open-label trial in four Italian large bone marrow transplant centers was conducted to assess the effectiveness of orange aroma in preventing NV related to DMSO. Patients were randomized to orange ice lollies, non-citrus ice lollies, and routine treatment (deep breaths) during reinfusion. Data on NV were collected up to 5 days after infusion; 69/98 patients were randomized: 23 to orange, 21 to non-citrus ice lollies, and 25 to routine treatment.
Introduction
Hematopoietic stem cell transplantation (HSCT) is standard treatment for many patients with congenital or acquired disorders of the hematopoietic system or with chemo-, radio-, or immuno-sensitive malignancies [1] . Worldwide, 50,417 HSCTs were done in 2006, 21,516 allogeneic (43 %) and 28,901 autologous (57 %) [1] .
For auto-SCT, hematopoietic stem cells (CD34+) are slowly frozen and stored in liquid nitrogen at −196°C with DMSO, which reduces cellular dehydration and osmotic stress [2] . Reinfusion may have several side effects such as hemolysis, anaphylactic reactions, kidney failure, high systolic and diastolic blood pressure, and bradycardia. However, gastrointestinal problems are the most frequent, particularly nausea and vomiting (NV), partly related to the characteristic garlic-like breath due to pulmonary excretion of the cryopreservative [3] [4] [5] [6] . DMSO and its metabolites (dimethylsulfone and dimethylsulfide) are excreted over 24 h after infusion, through urine, skin, and breathing [3] . The toxicity is proportional to the concentration and amount of DMSO [7] and increases with the number of bags and of cells harvested and with the patient's weight [2, 4, 6, 8] . A 10 % solution is generally used [2, 3] ; the 5 % solution with lower incidence of side effects is not recommended for lengthy storage since its safety has been assessed only over a few months [9, 10] .
Dimethyl sulfoxide may activate the vomiting center through the CTZ as soon as the agent is detected in the blood. This sensation may be compounded as it passes directly into the saliva and is then tasted and smelled upon entering the oral and nasal cavity [13] . Previous studies [14] showed that an unpleasant odor can be masked by a pleasant one presumably through lateral inhibitory connections in the local neuronal circuit of the olfactory bulb [15, 16] . The incidence of nausea with DMSO may range between 50 and 80 % [2] ; older patients are less affected [6] . This variability is probably related to the individual threshold and to the emetogenic property of the conditioning regimen. No drug seems to relieve NV associated with DMSO [11] with its negative impact on quality of life and on the risk of anorexia, dehydration, and electrolyte imbalance, up to renal failure [12] . Nausea, even mild, may negatively affect the quality of life in 25 % of patients [12] .
The smell and flavor of orange may reduce the patient's perception of its odor [5, 6] and thus NV (an unpleasant odor can be masked by a pleasant one [13, 14] ) although studies have given conflicting results. This suggested the hypothesis that DMSO-evoked activity map (odor map) might be inhibited by activation of mitral cells in the neighboring orange-responsive clusters. Potter's three-arm trial [6] showed that orange slices and aromatherapy with orange fragrance during the reinfusion of autologous stem cells were more effective than deep breathing-the "gold standard"-for reducing nausea, while Ndao's double-blind, placebo-controlled trial [11] found no benefit of respiratory aromatherapy with bergamot essential oil when added to standard supportive care. No studies explored the length of this inhibition; however, we might suppose that it is longer than the effective masking stimulus since Takahashi et al. [14] noted that, in many mitral-tufted cells, responses to odorants lasted for a long period even after cessation of the odor stimulation.
The aims of the study were to assess the effectiveness of orange aroma in preventing DMSO-related NV and to measure the incidence of NV and need for antiemetic rescue therapy in patients undergoing auto-SCT.
Methods

Study design and clinical setting
In this experimental, three-arm, open-label trial, patients undergoing auto-SCT were recruited in four large bone marrow transplant centers with more than 20 autologous transplantation/year in Piedmont (northern Italy) between June 2012 and January 2013. The study was approved by the ethics committees. All patients provided written informed consent.
Patients
Patients older than 18 years and able to use the Numerical Rating Scale (NRS) 0-100 and to give consent were included. Patients with known or suspected allergy to (or dislike of) oranges or ice lollies, expected requirement of three or more bags of autologous stem cells, nausea or vomiting not controlled at the end of the conditioning phase, dental pain, or hypersensitivity to cold were excluded (Fig. 1) .
Study procedures
Patients were randomized to three groups by randomization in blocks with step 6 (ratio 1:1:1) stratified by center using the software randomization.com [17] . Treatment codes were in sealed opaque envelopes.
Stem cells were stored in liquid nitrogen at −196°C with 10 % DMSO. Bags were thawed at 37°C and reinfusion started within a few minutes. All patients received premedication with steroids and during reinfusion were encouraged to breathe deeply (inhaling through the nose and exhaling through the mouth to expel DMSO). One group was randomized to orange ice lollies during reinfusion (orange group), another to non-citrus lollies (non-citrus group), and the third group to deep breaths (only-breathing group). Lollies sucking started and ended with infusion. Ice lollies were chosen in place of other modalities (i.e., orange in slices) to standardize the intervention and guarantee the administration of controlled quantity of orange aroma. Patients were given two ice lollies for each bag (the reinfusion lasts 10-15 min per bag, and it takes 5-8 min to finish an ice lolly), and they were free to ask for more. In the pilot study, the median consumption was 1.5 ice lollies [range [1] [2] [3] per bag. A nurse was present throughout the reinfusion.
We used commercial ice lollies with a 13-20 % concentration of aroma and all non-citrus fragrances except aniseed, which may be emetic [18] . Ice lollies were provided by the catering company or purchased by patients.
The following information was collected: (1) patients' main demographic and clinical characteristics, underlying disease, and previous transplantation (clinical records); recurrent headache (≥2 episodes/week), history, previous chemotherapy-induced nausea and vomiting, and motion or morning sickness (interview); and self-administered Zung Self-Rating Anxiety Scale (SAS) [19] . This consists of 20 items on a four-point scale (from a little to most of the time). The SAS score was converted into an anxiety index: scores ≥45 indicate anxiety, (2) treatment: conditioning regimen, chemotherapy cycle, premedication, and antiemetic prophylaxis (clinical records); number of bags and number of ice lollies sucked during the reinfusion; and (3) side effects: nausea (NRS 0-100), vomiting (number of episodes), and vital signs before and after reinfusion and any adverse reactions during the reinfusion.
From the transplantation day until day +5, each patient selfreported every 4 h nausea intensity (NRS 0-100), vomiting and retching episodes, and antiemetic rescue therapy. The median intensity of nausea was measured over 24 h; the number of episodes of vomiting and retching and of doses of antiemetic rescue therapy was recorded from the end of reinfusion.
In each ward, an experienced nurse was instructed for data collection. Consultancy was available throughout the data collection period.
Nausea was considered absent if <5, controlled if between 5 and 25, and not controlled if >25 [12] . Vomiting and retching were recorded separately and considered controlled if ≤2 episodes (vomiting and retching) at 24 h before reinfusion [12] and ≤1 episode during reinfusion.
Study outcomes
Primary This is the proportion of patients with controlled nausea (NRS ≤25) or vomiting.
Secondary
This is the proportion of patients with:
1. No nausea (NRS <5) or vomiting 2. Complete protection (no vomiting, no antiemetic rescue therapy, and controlled nausea) 3. Total control (no vomiting, no antiemetic rescue therapy, and no nausea)
After reinfusion, patients were assessed in up to 48 h (early period), to account for possible delayed effects of DMSO, and in the total period (0-120 h). Late phase refers to the 48-120 h after auto-SCT.
Statistical analysis
Continuous variables were expressed as median and interquartile ranges and were compared between groups using the Kruskal-Wallis test. Categorical variables were summarized as sums and percentages, and the χ 2 test with Yates' correction (or Fisher's exact test) was used for comparisons. Correlation was assessed using the Spearman coefficient.
A generalized least-square regression model was used to ascertain whether the interaction between groups and time with respect to nausea intensity was significant [21] . A
Analysis Allocation Enrolment
Assessed for eligibility (98) Randomized (69) Excluded ( (23) Deep breathing + noncitrus ice lolly (21) Only deep breathing (25) Analyzed (23) Analyzed (21) Analyzed (25) Eligible (75) No consent (6) 3 (3) Fig. 1 Screening, enrolment, and randomization correlation structure was specified to account for repeated measures over time (24, 48, 72, 96 , and 120 h after reinfusion) on the same patient. A continuous-time autoregressive of order 1 (CAR1) correlation structure resulted in the best model fit, based on Akaike Information Criterion (AIC) values. Age, sex, and number of stem cell bags infused were entered into the model. The linear relationship of nausea intensity over time was assessed using restricted cubic splines and tested with the Wald chi-square test. The data were analyzed with R version 2.15 [22] . All P values are two-sided, and significance of less than 0.05 was considered significant. Analyses were performed by intentionto-treat.
Sample size
The study was pilot-tested on 15 patients. In the pilot study, all patients in orange lollies had controlled nausea or vomiting, 83 % in non-citrus lollies, and 50 % in onlybreathing; with 23 patients in each group, we can show, with 90 % power, a 15 % difference in the proportion with controlled nausea or vomiting 48 h from auto-SCT, at a two-sided α level of 0.05 with Bonferroni correction for multiple comparisons.
Results
Ninety-eight patients were consecutively evaluated at entry and 69 (70 %) were recruited.
Over 60 % of patients were males, and almost half were conditioned with 200 mg/m 2 melphalan. None had electrolyte imbalance or had been treated with radiotherapy ( Table 1) .
The emetogenic potential of conditioning cycles was evaluated with the Hesketh score and was comparable, except for 100 mg/m 2 melphalan [20] . The number of patients with previous auto-SCT differed significantly among groups (P=0.005), but the incidence of not controlled nausea or vomiting 48 h post-transplant was similar in patients at the first vs second reinfusion (7.7 vs 13.3 %, P=0.458).
Premedication and antiemetic prophylaxis before reinfusion were given at standard doses; six patients received a three-drug premedication (three both in lollies and only-breathing groups) and ten a multidrug prophylaxis (six in lollies group and seven in only-breathing group). No patients were administered with drugs during infusion ( Table 2) .
Sixteen patients (70 %) in the orange group and 15 (71 %) in the non-citrus group had only one bag in 10 % DMSOcryopreserved PBSCs vs 21 (84 %) of the only-breathing group. Infusion rate ranged between 20 and 50 ml per minute throughout all the groups, and reinfusion lasted about 12 min with one bag and 28 with two. The median consumption of ice lollies was 1.5 [range 1-2.5] in the orange group and 1 [1-1.5] in the non-citrus group.
Overall, vital signs remained stable during reinfusion, except for a slight increase in systolic blood pressure in the orange group. Four patients reported an adverse event: a hypotensive crisis (non-citrus and only-breathing groups) and an episode of bradycardia (orange and non-citrus groups).
Nausea before, during, and after reinfusion Sixteen patients (80 %) in the orange group and 14 (78 %) in the non-citrus group reported no nausea during reinfusion vs 15 (71 %) of the only-breathing group. The numbers of patients with uncontrolled nausea during transplantation were comparable, though slightly lower in the ice lollies groups. At the end of reinfusion, 20 only-breathing patients (83 %) had no or controlled nausea vs 20 (95 %) in the non-citrus group and 21 (91 %) in the orange group. In all, 23 patients (30 %) did not report nausea.
In the first 48 h, over 90 % of ice lollies patients (21 (91 %) in the orange group and 20 (95 %) in the non-citrus group) had no or controlled nausea, compared to 76 % (19) of the onlybreathing group. About 30 % of patients randomized to ice lollies (8-35 % in the orange group and 6-29 % in the noncitrus group) reported nausea ≥5 compared to over 60 % (16) of the only-breathing group.
Forty-eight hours after infusion, 45 patients (65 %) reported nausea which was uncontrolled in 9 (36 %) only-breathing, 7 (30 %) orange, and 3 (14 %) non-citrus patients. Overall, 24 had nausea >25 at least once in the 5 days after transplantation. Generally, the nausea started to increase on the third day after reinfusion with a peak between 72 and 96 h, decreasing on the fifth day. The pattern for vomiting was similar. A borderline significant interaction (P=0.057) emerged between treatment and time: nausea remained almost unchanged in onlybreathing patients; while initially lower in the ice lollies groups, it raised over the next few days, up to the level of the only-breathing group on day 5.
Longitudinal regression analyses including treatment, age, sex, number of bags, and hours from transplant showed a significant difference between the three treatments (P = 0.0003), as well as an average increase of 3.8 points in nausea intensity every 24 h regardless of the treatment; female sex was a risk factor for nausea. Nausea intensity over time was significantly different between the ice lollies and onlybreathing (P=0.001), but not between orange and non-citrus, groups (P=0.428).
The longitudinal regression model showed a significant reduction of nausea with age and a rise with the number of bags infused. In the first 48 h after transplantation, median nausea was 2. During transplantation, six patients vomited in the orange group and four in the other groups.
Similarly, in the first 48 h, almost all ice lollies patients had no or controlled vomiting (22/23 orange and 20/21 non-citrus group) vs 15/25 (60 %) in the only-breathing group. Throughout the 5-day observation period, about half the patients who ate lollies reported at least one episode of vomiting (13 orange and 11 non-citrus group) compared to 80 % (20) of the only-breathing group.
Effectiveness of orange ice lollies
No significant difference in the primary endpoint (controlled nausea or vomiting) during reinfusion (P=1.000) or in the following 48 h (P=0.090) was observed between groups, although at 2 days post-transplant, these symptoms were still controlled only in the ice lollies patients (93 % controlled nausea and 96 % controlled vomiting) vs in the only-breathing group (76 % controlled nausea and 60 % controlled vomiting). Significant differences were observed for all secondary endpoints (Table 3) . During the first 48 h, significantly fewer patients had no nausea or vomiting in the onlybreathing group vs ice lollies (P=0.002). In fact, patients with complete protection were more than double in the ice lollies group compared to only-breathing group (P=0.003), and the pattern was similar for total control (P=0.017).
Antiemetic rescue therapy
In all, 23 (30 %) patients required antiemetic rescue therapy, in the ice lollies groups from the third day and in the onlybreathing group already in the first 48 h (Table 3) . During the 5 days, five patients in the orange, six in the non-citrus, and 12 in the only-breathing groups required rescue therapy, and respectively 10, 14, and 33 doses were given.
Discussion
This is the first study that assessed the effect of ice lollies in preventing DMSO-related NV in patients undergoing auto-SCT. Although we found no differences in controlled nausea or vomiting 48 h post-transplant and though considering the delayed emetogenic effect of melphalan, over 90 % of patients randomized to ice lollies had controlled nausea and almost all controlled vomiting (≤2 episodes), compared to respectively 76 and 60 % in the only-breathing group. The advantage was observable in the first 48 h [no nausea or vomiting in 89 % ice lollies vs 52 % only-breathing patients (P=0.002)]; furthermore, 57 % in the lollies groups had total control compared to 24 % only-breathing (P=0.017). These findings suggest that ice lollies may have an antiemetic effect, and a larger sample would probably have shown statistically significant differences in the primary endpoint.
The effect of ice lollies on NV mechanisms seems related to the vasoconstriction or reduction of taste perception due to cold, more than to the orange aroma. In fact, the proportions of patients with complete protection and total control were similar in the lollies groups; the differences for nausea intensity disappeared after adjustment for treatment, age, sex, number of bags, and hours from transplant (P=0.428), but remained when comparing with the only-breathing group (P=0.001). However, an increased NV control due to any aroma cannot be totally excluded since Takahashi et al. [14] demonstrated that a pleasant odor can mask an unpleasant one, presumably through lateral inhibitory connections in the local neuronal circuit of the olfactory bulb. The lack of effect on reduction of nausea from inhaled aromatherapy was already shown in adolescents undergoing auto-SCT [11] . 
The sum is greater than the total because some patients received multidrug treatment Gastrointestinal symptoms continue to be a problem in the first 48 h despite antiemetic prophylaxis: more than 40 % of patients reported nausea and 33 % (23) vomiting, in 16 cases despite no or controlled nausea, suggesting that the two symptoms are different, although related. In the first 48 h, only one patient in the ice lollies groups required antiemetic rescue vs 11 in the only-breathing group; the advantage was maintained despite comparable levels of delayed nausea.
After 48 h, symptom control was worse: more than 65 % of patients reported nausea, not controlled in 42 %, and about 60 % had at least one episode of vomiting (80 % in the onlybreathing group). The intensity of nausea increased with time (borderline significant interaction (P=0.057)): however, since it cannot be attributed to DMSO, whose half-life is only 24-36 h [2, 3] , other causes may be responsible such as mucositis whose preliminary symptoms are nausea and abdominal cramps [23] . Its incidence ranges between 75 and 85 %, and it usually arises 3 to 5 days after transplant [19] [20] [21] [22] . The delayed nausea may depend on P-dependent (undecapeptide tachykinin acting as a sensory neurotransmitter in the central nervous system and as a local hormone in the gastrointestinal tract, involved in pain and vomiting) mechanism, and therefore, it might be caused by cytotoxic therapy-induced mucosal damage (CIMD) [23] . Thus, the nausea is initially linked to the cryopreservative and later to gastrointestinal mucosal damage [23] .
The intensity of nausea increased with the number of bags infused [7] ; female sex was confirmed as an independent risk factor for nausea (P=0.028) and a likely predictor of mucositis [24, 25] .
Since the amount of stem cells needed (and the number of bags) increases with body weight, a parallel increase in nausea was expected in patients infused with two bags: differently from Potter's study [6] , we found no correlation. However, our population was hardly comparable to that of Potter as only four patients (6 %) weighed more than 90 kg compared to 27 (45 %) in the American study.
Strengths and limitations
The central randomization prevented a selection bias, and stratification by center avoided a center effect. A major strength of the study is the generalization of the results to Italian patients undergoing auto-SCT, since patients' main demographic and clinical characteristics and chemotherapy cycles are comparable across centers.
No data was lost due to the excellent patients' collaboration, and intervention (administration of ice lollies) was more comparable than in previous studies [6] . The three-arm design allowed to assess whether the efficacy of the intervention was related to the vasoconstrictive action of ice or aroma.
The study was limited by its small sample size and the predominance of male patients, although the prevalence of auto-SCT is considerably higher in men [26, 27] . Moreover, we did not record the total dose of DMSO in milligrams per kilogram which can affect nausea and vomiting; however, 31 ice lollies patients (70 %) (16 (70 %) orange and 15 (71 %) non-citrus) had only one bag in DMSO-cryopreserved PBSCs vs 21 (84 %) in the only-breathing group; thus, the latter was overall less exposed to DMSO.
Conclusion
Although no differences were observed for controlled nausea or vomiting, the results suggest the potential efficacy of ice in raising the proportion of patients with no nausea or vomiting due to DMSO and in reducing the need for antiemetic rescue therapy. However, larger samples are needed to confirm whether the effect was due to the vasoconstrictive action of ice rather than the aroma itself, testing flavors in different forms (ice lollies, candies, or lollipops).
The need of antiemetic prophylaxis of conditioning cycles should be revised since half the patients came to the transplant day with uncontrolled nausea or vomiting.
